Report Type: Therapy Reports
Report Category: Women's Health
Report Subcategory: Atrophic Vaginitis or Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy
Price: 2999.00
Date: January 2022

Atrophic Vaginitis or Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Atrophic Vaginitis or Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy
Atrophic Vaginitis or Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy is thinning, drying and inflammation of the vaginal walls that may occur when your body has less estrogen, most often after menopause.

Top 10 Companies:
Johnson & Johnson
Pfizer Inc
Bayer AG
Novartis AG
Novo Nordisk AS
Teva Pharmaceutical Industries Ltd
Shionogi & Co Ltd
Endo International Plc
Amneal Pharmaceuticals Inc
Hisamitsu Pharmaceutical Co Inc